RLY-2608 is under clinical development by Relay Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RLY-2608’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RLY-2608 overview

RLY-2608 is under development for the treatment of solid tumors, metastatic breast cancer, HR positive/human epidermal growth factor receptor 2 negative breast cancer (HER2- Breast Cancer). It is administered through oral route. It is a small molecule and acts by targeting H1047X, E542X and E545X mutant phosphoinositide 3-kinase (PI3K alpha). The drug candidate is being developed based on dynamo platform.

Relay Therapeutics overview

Relay Therapeutics ) is a clinical-stage precision medicines company that develops oncology and generic drugs. The company’s pipeline products include RLY-4008, RLY-2608, GDC-1971, RLY-5836 and GDC-1971 for the treatment of a variety of cancers. Its RLY-4008 is an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), for patients with advanced or metastatic FGFR2-altered solid tumors. The company utilizes the Dynamo platform, which integrates an array of leading-edge computational and experimental approaches designed for drug-protein targets. Relay Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of RLY-2608’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.